Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
+$0.16 today
- Market cap
- $2.16B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
Volume 0.68M
Average 0.94M
CLDX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Celldex Therapeutics, Inc.NASDAQ: CLDX
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$74.4M, compared with -$66.22M a year earlier. Trailing-twelve-month EBITDA was -$305.37M.
Context
- EBITDA amounted to 17028.0% of revenue in FY2025, up 14824.5 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of -$267.45M (-4.7%) for the fiscal year ending Dec 2026, a step up from the -65.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$74.4M-2.5% QoQ
- Last fiscal yearDec 2025
- -$255.42M-65.1% YoY
- LTMSep 2026
- -$305.37M-38.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.3% | +3.5% | +15.8 pp |
| 1 year | -65.1% | -4.7% | +60.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (255.42M) USD
- Year-over-year change
- -65.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (255.42M) | -65.1% |
| FY2024 | 2024-12-31 | (154.69M) | -11.3% |
| FY2023 | 2023-12-31 | (139.03M) | -33.4% |
| FY2022 | 2022-12-31 | (104.2M) | -57.7% |
| FY2021 | 2021-12-31 | (66.08M) | — |
EBITDA vs competitors
How CLDX compares with its peers on the latest reported figures
- CLDX's LTM Sep 2026 EBITDA of -$305.37M is the 9th highest of the 10 companies compared; the peer median is -$50.64M.
- Its year-over-year change of -38.1% is the 7th highest of 9, against a peer median of -10.6%.
- EBITDA amounts to 272652.7% of revenue for CLDX, versus a peer median of 102.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $322.61M | +243.1% | — | 46.0% | |
| LTM Mar 2026 | $127.04M | +256.7% | — | 102.6% | |
| LTM Mar 2026 | $34.88M | +463.6% | — | 48.0% | |
| LTM Jun 2024 | -$36.06M | — | — | 4420.7% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$67.05M | -25.2% | — | — | |
| LTM Jun 2026 | -$123.6M | -14.3% | — | 117.7% | |
| LTM Sep 2026 | -$284.54M | -45.7% | — | — | |
| LTM Sep 2026 | -$305.37M | -38.1% | — | 272652.7% | |
| LTM Jun 2026 | -$419M | -48.6% | — | 358.1% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CLDX) | -$50.64M | -10.6% | — | 102.6% | |
Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.65M | 2.36M | 6.88M | 7.02M | 1.5M |
| Cost of Revenue | 53.31M | 82.26M | 118.01M | 163.55M | 0 |
| Gross Profit | (48.66M) | (79.9M) | (111.13M) | (156.53M) | 1.5M |
| Gross Margin | -1046.2% | -3389.9% | -1614.5% | -2229.8% | 100.0% |
| Research & Development | 56.81M | 82.26M | 118.01M | 163.55M | 245.1M |
| Selling, General & Admin | 20.49M | 27.2M | 30.91M | 38.55M | 43.8M |
| Operating Expenses | 22.58M | 35.33M | 43.41M | 38.55M | 288.9M |
| Depreciation & Amortization | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| EBITDA | (66.08M) | (104.2M) | (139.03M) | (154.69M) | (255.42M) |
| EBITDA Margin | -1420.8% | -4420.9% | -2020.0% | -2203.5% | -17028.0% |
| Operating Income | (71.24M) | (115.23M) | (154.54M) | (195.08M) | (287.4M) |
| Operating Margin | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -19160.0% |
| Interest Income | 505K | 2.91M | 13.11M | 37.22M | 28.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 505K | 2.91M | 13.11M | 37.22M | 28.6M |
| Income Before Tax | (70.74M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Pre-Tax Margin | -1520.9% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| Income Tax Expense | (227K) | 0 | 0 | 0 | 0 |
| Net Income | (70.51M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Net Margin | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| EPS (Basic) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| EPS (Diluted) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| Weighted Avg Shares | 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
| Weighted Avg Shares (Diluted) | 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
Celldex Therapeutics, Inc.
NASDAQ:CLDX
Intrinsic Alpha fair value
Locked
Current Price
$27.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.